DexCom (DXCM) Revenue — Quarter Ended Dec 31, 2025
Revenue increased in the quarter compared to both the prior quarter and the same quarter last year. The trailing twelve-month revenue also showed growth.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue increased in the quarter compared to both the prior quarter and the same quarter last year. The trailing twelve-month revenue also showed growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.3B
Revenue reported for this quarter.
Quarter-over-quarter
+4.2%
Change from the immediately preceding quarter.
Year-over-year
+13.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $1B | +12.5% |
| Jun 30, 2025 | $1.2B | +15.2% |
| Sep 30, 2025 | $1.2B | +21.6% |
| Dec 31, 2025 | $1.3B | +13.1% |
Revenue performance
The quarter's revenue was higher than the immediately preceding quarter, continuing the upward trend observed through the year.
Quarterly comparison
Compared to the same quarter one year earlier, revenue also increased, reflecting sustained growth.
What to watch
The filing discusses liquidity sources and capital requirements, noting that future performance depends on international expansion and efficient scaling of operations.